16 October 2024
16 October 2024
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor.
The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
The deal aims to fill a crucial gap in medical countermeasures for radiation exposure.
Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.
Bayer notches up pressure on rival Astellas’ Veozah with an EU marketing authorisation application for its hot flash relief pill.
The NDA submission is supported by data from the Phase III ENVISION study.
Onychomycosis is a serious fungal infection impacting an estimated 5.5% of the world's population.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
